DE59005517D1 - Doppelt beschichtete Granulate. - Google Patents

Doppelt beschichtete Granulate.

Info

Publication number
DE59005517D1
DE59005517D1 DE59005517T DE59005517T DE59005517D1 DE 59005517 D1 DE59005517 D1 DE 59005517D1 DE 59005517 T DE59005517 T DE 59005517T DE 59005517 T DE59005517 T DE 59005517T DE 59005517 D1 DE59005517 D1 DE 59005517D1
Authority
DE
Germany
Prior art keywords
coated granules
double coated
capsules
granules
double
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE59005517T
Other languages
English (en)
Inventor
Dagmar Dr Wirth
Christian Bucher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Ciba Geigy AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy AG filed Critical Ciba Geigy AG
Application granted granted Critical
Publication of DE59005517D1 publication Critical patent/DE59005517D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Glanulating (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
DE59005517T 1989-09-07 1990-08-30 Doppelt beschichtete Granulate. Expired - Lifetime DE59005517D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH324589 1989-09-07

Publications (1)

Publication Number Publication Date
DE59005517D1 true DE59005517D1 (de) 1994-06-01

Family

ID=4251793

Family Applications (1)

Application Number Title Priority Date Filing Date
DE59005517T Expired - Lifetime DE59005517D1 (de) 1989-09-07 1990-08-30 Doppelt beschichtete Granulate.

Country Status (21)

Country Link
US (1) US5096717A (de)
EP (1) EP0421921B1 (de)
JP (1) JP3009713B2 (de)
KR (1) KR910005852A (de)
AT (1) ATE104856T1 (de)
AU (1) AU623036B2 (de)
CA (1) CA2024631C (de)
DD (1) DD298049A5 (de)
DE (1) DE59005517D1 (de)
DK (1) DK0421921T3 (de)
ES (1) ES2052228T3 (de)
FI (1) FI93169C (de)
HU (1) HU207447B (de)
IE (1) IE63668B1 (de)
IL (1) IL95558A (de)
MX (1) MX22254A (de)
NO (1) NO176646C (de)
NZ (1) NZ235187A (de)
PH (1) PH27186A (de)
PT (1) PT95209B (de)
ZA (1) ZA907100B (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0520119A1 (de) * 1991-06-17 1992-12-30 Spirig Ag Pharmazeutische Präparate Neue orale Diclofenaczubereitung
US6764697B1 (en) * 1991-06-27 2004-07-20 Alza Corporation System for delaying drug delivery up to seven hours
EP0596962A4 (en) * 1991-07-24 1997-01-15 Enzacor Pty Ltd Therapeutic compositions and methods.
ES2149781T3 (es) * 1991-11-22 2000-11-16 Procter & Gamble Pharma Composiciones de risedronato de liberacion retardada.
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5472712A (en) * 1991-12-24 1995-12-05 Euroceltique, S.A. Controlled-release formulations coated with aqueous dispersions of ethylcellulose
US5681585A (en) 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5968551A (en) * 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
FR2687291B1 (fr) * 1992-02-17 1994-06-03 Sfbd Vivis Aliment pour sportif et son procede de fabrication.
TW237386B (de) * 1992-04-15 1995-01-01 Ciba Geigy
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
IT1260505B (it) * 1992-06-01 1996-04-09 Poli Ind Chimica Spa Sistemi farmaceutici orali a cessione ritardata per il rilascio specifico nel colon
DE4236090C1 (de) * 1992-10-26 1994-01-05 Asta Medica Arzneimittel Pharmazeutische Zubereitung für die Fluoridionen-Versorgung
US5993860A (en) * 1993-06-17 1999-11-30 Venture Lending NSADI delivery employing a powdered hydrocolloid gum obtainable from higher plants
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
TW390813B (en) * 1994-04-29 2000-05-21 Merck & Co Inc Wet granulation formulation for bisphosphonic acids
US20010007863A1 (en) * 1998-06-18 2001-07-12 Merck & Co., Inc. Wet granulation formulation for bisphosphonic acids
US5766623A (en) * 1996-03-25 1998-06-16 State Of Oregon Acting By And Through The Oregon State Board Of Higher Education On Behalf Of Oregon State University Compactable self-sealing drug delivery agents
DE19637082A1 (de) 1996-09-12 1998-03-19 Boehringer Mannheim Gmbh Schnellzerfallende Pellets
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US5891474A (en) * 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
WO1998056360A2 (en) * 1997-06-11 1998-12-17 The Procter & Gamble Company Film-coated tablet for improved upper gastrointestinal tract safety
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
US8563522B2 (en) * 1997-07-08 2013-10-22 The Iams Company Method of maintaining and/or attenuating a decline in quality of life
US20020035071A1 (en) * 1997-07-08 2002-03-21 Josef Pitha Mimicking the metabolic effects of caloric restriction by administration of glucose antimetabolites
US20060116330A1 (en) * 1997-07-08 2006-06-01 The Iams Company Methods of mimicking the metabolic effects of caloric restriction by administration of mannoheptulose
US6197331B1 (en) 1997-07-24 2001-03-06 Perio Products Ltd. Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE19732903A1 (de) 1997-07-30 1999-02-04 Falk Pharma Gmbh Pellet-Formulierung zur Behandlung des Intestinaltraktes
US6984400B2 (en) * 1998-07-14 2006-01-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of treating restenosis using bisphosphonate nanoparticles
IL125336A0 (en) 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
US6160165A (en) * 1998-12-10 2000-12-12 Aesgen, Inc. Method for preparation of disodium pamidronate
US6794536B1 (en) 1998-12-10 2004-09-21 Aesqen, Inc. Method for preparation of disodium pamidronate
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
AR021347A1 (es) 1999-10-20 2002-07-17 Cipla Ltd Una composicion farmaceutica que contiene acido(s) bisfosfoncio o sal(es) del mismo y un proceso de preparacion de la misma
AU2127200A (en) * 1999-11-02 2001-05-14 Cipla Limited A pharmaceutical composition containing bisphosphonic acid(s) or salt(s) thereofand a process of preparing thereof
PL196485B1 (pl) * 2000-05-11 2008-01-31 Inst Farmaceutyczny Stała doustna kompozycja farmaceutyczna zawierająca aminową pochodną kwasu bisfosfonowego i sposób jej wytwarzania
US20030190360A1 (en) * 2001-03-13 2003-10-09 Baichwal Anand R. Chronotherapeutic dosage forms containing glucocorticosteroid and methods of treatment
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
US8168170B2 (en) * 2002-10-03 2012-05-01 The Procter And Gamble Company Compositions having an inner core and at least three surrounding layers
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US20050118267A1 (en) * 2003-09-19 2005-06-02 Penwest Pharmaceuticals Co. Chronotherapeutic dosage forms
NZ545921A (en) * 2003-09-19 2009-09-25 Penwest Pharmaceuticals Co Delayed released dosage forms
US20050152884A1 (en) * 2003-12-19 2005-07-14 The Procter & Gamble Company Canine probiotic Bifidobacteria globosum
US7785635B1 (en) 2003-12-19 2010-08-31 The Procter & Gamble Company Methods of use of probiotic lactobacilli for companion animals
US20050158294A1 (en) * 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) * 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
US8894991B2 (en) * 2003-12-19 2014-11-25 The Iams Company Canine probiotic Lactobacilli
SI21637A (sl) * 2003-12-23 2005-06-30 LEK farmacevtska dru�ba d.d. Farmacevtska oblika z nadzorovanim sproščanjem
WO2006018033A1 (en) * 2004-08-20 2006-02-23 Mepha Ag Formulations of bisphosphonates
AU2006253006B8 (en) * 2005-05-31 2011-09-15 Alimentary Health Ltd Feline probiotic Lactobacilli
BRPI0611492B1 (pt) * 2005-05-31 2021-10-13 Mars, Incorporated Bifidobactéria probiótica felina
US7473684B2 (en) 2005-09-16 2009-01-06 Selamine Limited Bisphosphonate formulation
GB0624090D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amine salts
GB0624084D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril amino acid salts
GB0624087D0 (en) * 2006-12-01 2007-01-10 Selamine Ltd Ramipril combination salt
MX2009008166A (es) 2007-02-01 2009-08-12 Iams Company Metodo para disminuir la inflamacion y estres en un mamifero usando antimetabolitos de glucosa, aguacate o extractos de aguacate.
US9771199B2 (en) 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
DE102009033621A1 (de) 2009-07-17 2011-01-20 Add Technologies Ltd. Trennschichten für pharmazeutische Zubereitungen zur Verhinderung von Wechselwirkungen zwischen Arzneistoffen und pharmazeutisch-technologischen Hilfsstoffen
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US8663671B2 (en) 2009-11-05 2014-03-04 Philip Morris Usa Inc. Methods and compositions for producing hydrogel capsules coated for low permeability and physical integrity
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CA2936741C (en) 2014-10-31 2018-11-06 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
PH18946A (en) * 1983-04-21 1985-11-14 Elan Corp Plc Controlled absorption pharmaceutical composition
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US4983401A (en) * 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings

Also Published As

Publication number Publication date
IL95558A (en) 1995-08-31
JP3009713B2 (ja) 2000-02-14
IL95558A0 (en) 1991-06-30
AU623036B2 (en) 1992-04-30
PT95209A (pt) 1991-05-22
HUT59008A (en) 1992-04-28
FI93169B (fi) 1994-11-30
EP0421921B1 (de) 1994-04-27
KR910005852A (ko) 1991-04-27
US5096717A (en) 1992-03-17
CA2024631A1 (en) 1991-03-08
AU6228390A (en) 1991-03-14
NO176646C (no) 1995-05-10
HU905812D0 (en) 1991-03-28
IE903239A1 (en) 1991-03-13
NZ235187A (en) 1992-03-26
CA2024631C (en) 2000-11-21
FI93169C (fi) 1995-03-10
PH27186A (en) 1993-04-16
ATE104856T1 (de) 1994-05-15
NO903892L (no) 1991-03-08
HU207447B (en) 1993-04-28
NO903892D0 (no) 1990-09-06
IE63668B1 (en) 1995-05-31
DK0421921T3 (da) 1994-05-30
FI904341A0 (fi) 1990-09-03
EP0421921A1 (de) 1991-04-10
NO176646B (no) 1995-01-30
ZA907100B (en) 1991-05-29
DD298049A5 (de) 1992-02-06
MX22254A (es) 1993-12-01
ES2052228T3 (es) 1994-07-01
PT95209B (pt) 1998-06-30
JPH0399016A (ja) 1991-04-24

Similar Documents

Publication Publication Date Title
DE59005517D1 (de) Doppelt beschichtete Granulate.
NO871790D0 (no) Fremgangsmaate for fremstilling av et oralt farmasoeytisk preparat.
NO910923L (no) Trifunksjonell antistofflignende forbindelse som et kombinert diagnostisk og terapeutisk middel.
NO882002D0 (no) Fremgangsmaate for fremstilling av sfaeriske partikler.
NO881728D0 (no) Fremgangsmaate for fremstilling av tverrbundne polymerpartikler.
NO863671D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydro-2-heterocykloalkylpyrido(4,3)indoler.
NO881643L (no) Fremgangsmaate for fremstilling av hoeystabile mykgelatinkapsler for terapeutiske formaal.
NO883122L (no) Fremgangsmaate for fremstilling av terapeutisk aktive arylamid-derivater.
NO167797C (no) Analogifremgangsmaate for fremstilling av et terapeutisk aktivt nitrometan.
NO167386C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive sulfider med anvendelse som immunmodulatorer.
NO910869D0 (no) Fremgangsmaate for desinfeksjon av medisinsk avstoepningsmasse.
NO904800L (no) Fremgangsmaate for fremstilling av terapeutisk aktive karbamater.
NO167802C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive benzotiazepinderivater.
NO158579C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktivt n-(2-metoksyetyl)-noroksymorfon.
NO884162D0 (no) Fremgangsmaate for fremstilling av polymerpartikler.
NO880325D0 (no) Fremgangsmaate for fremstilling av n,n-(dibenzoheksatrienylen)ureaer.
NO168247C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 5-metoksy-alkyl-ammonium-tetrahydrofuraner.
NO901893D0 (no) Fremgangsmaate for fremstilling av penemforbindelser.
NO892871D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.
NO900119D0 (no) Fremgangsmaate for fremstilling av 7-aryl- og heteroaryletere av desacetylforskolin, og deres anvendelse som medikamenter.
NO893423D0 (no) Fremgangsmaate for fremstilling og anvendelse av decaplanin, et nytt glycopeptid-antibiotika.
NO166447C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomt n-(1-cyclohexenylmethyl-2-pyrrolidinylmethyl)-8-ethylsulfonyl-1,5-benzodioxepan-6-carboxamid.
NO170545C (no) Analogifremgangsmaate for fremstilling av terapeutisk virksomme 6,21-dimethyl-19-nor-pregna-diener
NO880841D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive forbindelser.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: NOVARTIS AG, BASEL, CH